Skip to content
Pyrukynd(mitapivat)
Pyrukynd (mitapivat) is a small molecule pharmaceutical. Mitapivat was first approved as Pyrukynd on 2022-02-17. It is used to treat hemolytic anemia in the USA. It has been approved in Europe to treat hemolytic anemia and inborn genetic diseases. It is known to target pyruvate kinase PKM.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
Trade Name
FDA
EMA
Pyrukynd
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mitapivat sulfate
Tradename
Company
Number
Date
Products
PYRUKYNDAgios PharmaceuticalsN-216196 RX2022-02-17
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
pyrukyndNew Drug Application2022-02-23
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hemolytic anemia—D000743D55-D59
Agency Specific
FDA
EMA
Expiration
Code
MITAPIVAT SULFATE, PYRUKYND, AGIOS PHARMS INC
2029-02-17ODE-392
2027-02-17NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Mitapivat Sulfate, Pyrukynd, Agios Pharms Inc
112546522038-11-21DS, DP
112349762038-10-11U-3321
91937012032-10-26U-3319
96820802032-05-03U-3319
99809612032-05-03U-3319
106321142032-05-03U-3320
87854502031-02-24DS, DP
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hemolytic anemiaD000743D55-D59114——5
Sickle cell anemiaD000755EFO_0000697D57221——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThalassemiaD013789EFO_1001996D56—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—9————9
Hepatic insufficiencyD0485501————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMITAPIVAT
INNmitapivat
Description
Mitapivat, sold under the brand name Pyrukynd, is a medication used to treat hemolytic anemia. It is taken as the sulfate hydrate salt by mouth. Mitapivat is a pyruvate kinase activator.
Classification
Small molecule
Drug classpyruvate kinase activators
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1
Identifiers
PDB—
CAS-ID1260075-17-9
RxCUI—
ChEMBL IDCHEMBL4299940
ChEBI ID—
PubChem CID59634741
DrugBankDB16236
UNII ID2WTV10SIKH (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PKM
PKM
Organism
Homo sapiens
Gene name
PKM
Gene synonyms
OIP3, PK2, PK3, PKM2
NCBI Gene ID
5315
Protein name
pyruvate kinase PKM
Protein synonyms
CTHBP, Cytosolic thyroid hormone-binding protein, epididymis secretory protein Li 30, OIP-3, OPA-interacting protein 3, p58, PK, muscle type, Pyruvate kinase 2/3, pyruvate kinase isozymes M1/M2, Pyruvate kinase muscle isozyme, pyruvate kinase, muscle, THBP1, Threonine-protein kinase PKM2, Thyroid hormone-binding protein 1, thyroid hormone-binding protein, cytosolic, Tumor M2-PK, Tyrosine-protein kinase PKM2
Uniprot ID
P14618
Mouse ortholog
Pkm (18746)
pyruvate kinase PKM (P52480)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 117 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details